Menu

Infographic: Two Pain Paths Diverge in the Body

The acute pain that results from injury or disease is very different from chronic pain.

Dec 31, 2017
Mark R. Hutchinson

© THOM GRAVES

Persistent pain continues even after the damage is resolved, or in some cases, in the absence of an acute injury in the first place. The difference between this and acute pain, also known as nociception, researchers are learning, comes down to the neural mechanisms that trigger these distinct signals in the brain.

Nociception
Acute pain is caused by the activation of nociceptive sensory neurons in the periphery. These neurons trigger the firing of a series of connected somatosensory neurons up the spinal cord and into the brain, transferring information about the intensity and duration of the painful stimulus.

Persistent pain
Pain that persists long after or in the absence of injury can result from the misfiring of the normal nociceptive pathway. This can be triggered in the periphery—sometimes arising from a neutral stimulus, such as light touch—with the signal becoming amplified on its way to the brain. Alternatively, persistent pain can arise in the absence of any stimulus with the firing of neurons in spinal cord or brain circuits responsible for pain processing. Immune-like cells of the central nervous system known as glia are now recognized to contribute to the aberrant neural activation that causes persistent pain.

Glia’s Role in Persistent Pain

Microglia release cytokines and other proinflammatory molecules, as well as detect signaling factors from peripheral immune cells (1). Together, these signals can enhance the release of excitatory neurotransmitters from pain-transmitting neurons, leading to increased neuronal firing (2). Normally, when glial cells called astrocytes detect an increase in the extracellular concentrations of neurotransmitters, their cellular processes called endfeet begin to take up greater amounts of the molecules in an attempt to bring the hyperactive synapses under control (3). In persistent pain, these cells contain fewer of the molecular transporters responsible for this neurotransmitter removal. Glial cytokines and chemokines can also cause greater numbers of receptors to be displayed on the postsynaptic terminal of the pain-transmitting synapse, further promoting neuroexcitability (4).

© THOM GRAVES. REDRAWN FROM FIGURE 1 IN BIOL PSYCHIATRY, 65:732-741, 2009.

Read the full story.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.